Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial is a research paper published in medRxiv (2021). On theSindex it has a DataRank of 0.877. It has been cited 14 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.470
From 9 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.
National Institutes of Health
Grant: 5UL1TR002243-05
Vanderbilt Institute for Clinical and Translational Research (VICTR)
National Institutes of Health
Grant: 3UM1AI148684-03S1
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
National Institutes of Health
Grant: 3UM1AI148373-02S1
Kaiser Washington Vaccine and Treatment Evaluation Unit
National Institutes of Health
Grant: 5UM1AI148576-02
Vaccine and Treatment Evaluation Units
NIAID NIH HHS
Grant: UM1 AI148576
NIAID NIH HHS
Grant: UM1 AI148373
NIAID NIH HHS
Grant: UM1 AI148684
NIAID NIH HHS
Grant: HHSN272201500002C
NCATS NIH HHS
Grant: UL1 TR002243
Influential Citations
2
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals